VPA10425/009/001

Hedylon 5 mg tablets for dogs and cats

| Variation | Summary | Date |
|----------------------|---|----------|
| Vet - A1 a) | VNRA - Vet - A1 a) A1 a) Administrative changes - Change in the name or address of - the marketing authorisation holder | 27/10/25 |
| Vet - B44 a) | VNRA - Vet - B44 a) Vet - B44 a) - Submission of a Ph. Eur. CEP for:— active substance;— starting material, reagent or intermediate used in the manufacturing process of the active substance;— excipient - Updated cerificate | 13/08/25 |
| Vet - C1 | VNRA - Vet - C1 - Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) - C1 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Change(s) in the name or address or contact details of a qualified person for pharmacovigilance (QPPV) | 19/06/25 |
| Vet - C6 | VNRA - Vet - C6 - Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 - C6 Changes to the safety, efficacy and pharmacovigilance part of the dossier: Introduction of a summary of the PSMF or changes to the summary of the PSMF not already covered elsewhere in the Annex to Regulation (EU) 2021/17 | 19/06/25 |
| Vet - F.II.f.1 a) 1. | VRA-R - Vet - F.II.f.1 a) 1 a) Extension of the shelf life of the finished product 1. As packaged for sale (supported by real time data) - F.II.f.1 a) 1. Quality Changes -Stability - Change in the shelf-life or storage conditions of the finished product - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data) | 01/12/22 |
| B.III.1.a.3 | IAin - B.III.1.a.3 - 3. New certificate from a new manufacturer (replacement or addition) - B.III.1.a.3 - QUALITY CHANGES - CEP/TSE/MONOGRAPHS - Submission of a new or updated Ph. Eur. Certificate of suitability or deletion of Ph. Eur. certificate of suitability: For an active substance For a starting material/reagent/intermediate used in the manufacturing process of the active substance For an excipient - European Pharmacopoeial Certificate of Suitability to the relevant Ph. Eur. Monograph New certificate from a new manufacturer (replacement or addition) | 14/02/22 |